Search academic texts

Registration Number

0220U100079, 0117U001045 , R & D reports

Title

Define the role of the cyclooxygenase-2 selective inhibitor along with the ionizing radiation in blocking of tumor angiogenesis for development of new technologies of the combined radiation and anti-angiogenesis therapy of oncological diseases

popup.stage_title

Head

Mitryaeva Nataliya A., Доктор біологічних наук
Starenkiy Viktor P., Доктор медичних наук

Registration Date

09-01-2020

Organization

State Organization "Grigoriev Institute for Medical Radiologiy of the National Academy of Medical Sciences of Ukraine"

popup.description2

 Object of research: experimental study of the effect of X-radiation and the combined effect of X-radiation and a COX-2 inhibitor - meloxivet on the content of VEGF and PGE-2. The purpose of the work: is to determine the mechanisms of participation of cyclooxygenase-2 selective inhibitors in combination with ionizing radiation in blocking tumor angiogenesis to substantiate their role in radiation therapy of cancer and to develop recommendations for new technologies of combined radiation and lung cancer of the lung. Methods of research and equipment: clinical and instrumental, immunoenzymometric, electron-microscopic, dosimetric, statistical; the universal dosimeter UNIDOS_E, the linear accelerator Clinac-600, RUM-17. Theoretical and practical results: it was found that the radiation therapy technology in combination with a COX-2 inhibitor is more effective in increasing the frequency of the objective response, an increase in relapse-free one-year survival by 29% for NSCLC and 14% of SCCHN comparison with radiation therapy. A method has been developed for the treatment of squamous cell carcinoma, which is based on the radiation therapy technology in combination with a COX-2 inhibitor - ranselex of patients with NSCLC and SCCHN. The mechanisms of the influence of different doses of ionizing radiation on the level of VEGF in the blood serum of rat tumor carriers were determined: at a total dose of 1 Gy, a stimulation of the process of neoangiogenesis is observed, at a total dose of 10 Gy, a slowdown of the process. Novelty: for the first time, new data have been obtained on the effect of the combined effects of radiation therapy with ranselex on the content of the levels of pro-angiogenic factors VEGF, COX-2 and PGE-2 in the blood serum of patients with NSCLC and SCCHN, depending on the objective response to monitor the effectiveness of treatment. Domain of usage: oncology and radiation oncology.

Product Description

popup.authors

Artyukh Sergey V.
Bilozor Nataliya V.
Grebinyk Lidiya V.
Kancedal Elena Nikolayevna
Kondrashova Olena I.
Kurov Alexsandr M.
Lukashova Olga P.
Mitryayeva Nataliya А.
Makaruk Olena V.
Maslennikova Olena L.
Potapova Tatyana I.
Pshyshevska Ludmila M.
Starenkiy Viktor P.
Teslenko Irina M.
Tkathenko Alla A.
Uzlenkova Nataliya Ye.

popup.nrat_date

2020-04-02